MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 44 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No. 1 for cancer care in the U.S. News & World Report’s “Best Hospital’s” survey. It has ranked as one of the nation’s top two hospitals since the survey began in 1990, and has ranked first 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
ARCH Venture Partners
ARCH Venture Partners, one of the largest early stage technology venture firms in the U.S., invests in the development of seed and early stage advanced technology companies that have the potential to grow rapidly into successful businesses. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions, corporate research groups and national laboratories.
ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH’s limited partners include major corporations, pension funds, university endowments, financial institutions, and private investors.
The partnership is led by eight managing directors, including four co-founders who have worked together for more than 25 years. They are supported by a team of partners, venture partners, associates, and technology specialists.
Canaan Partners is a global venture capital firm that invests in people with visionary ideas. The kind that not only result in new and valuable technology, but game-changing healthcare startups as well.
We were early investors in some of the world's leading technology companies, including PrimeSense, SuccessFactors and Lending Club and healthcare stars like Cerexa, Chimerix and Advanced BioHealing.
All of which makes one thing perfectly clear. When people are your priority, good things happen.
GreatPoint Ventures is a thesis driven venture capital firm that invests in solutions to important global problems. GreatPoint looks for driven entrepreneurs and start-up businesses addressing clear pain-points in industry with innovative technology. Comprised of entrepreneurs and operators, GreatPoint actively collaborates with founders and their teams to build great businesses. GreatPoint has invested in the world's fastest database, the leader in predictive analytics for the industrial world, a marketplace to reinvent the US healthcare system, and pioneers in cancer diagnostics and therapeutics, among other break-through innovations.
Helsinn Investment Fund
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. Shire strive’s to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Shire employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc. (NYSE:ARE) is an urban office REIT uniquely focused on world-class collaborative science and technology campuses in AAA innovation cluster locations with a total market capitalization of $10.9 billion as of December 31, 2015, and an asset base of 32.0 million square feet, including 20.1 million RSF of operating properties and development and redevelopment projects (under construction or pre-construction), as well as an additional 11.9 million square feet of future ground-up development projects. Alexandria pioneered this niche in 1994 and has since established a dominant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. Alexandria is known for its high-quality and diverse tenant base, with approximately 54% of total annualized base rent as of December 31, 2015, generated from investment-grade tenants – a REIT industry-leading percentage. Alexandria has a longstanding and proven track record of developing Class A assets clustered in urban science and technology campuses that provide its innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. We believe these advantages result in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
William Marsh Rice University
At Rice, we believe nothing is impossible. There is no "what if” that cannot become "what is.” It just takes radical thinking to get there and a community of brilliant dreamers and doers to lead the way. That’s why we challenge convention at every turn: from the very way we live, to the teaching and research approaches we take, to the solutions we find, to the way we collaborate, to the way we insist on advancing tomorrow’s thinking, because today’s is not far enough. It sounds like a lot from a small university, but that’s what makes us special. That’s what gives us Unconventional Wisdom.